Alderley Park, 17 February 2023 – Blueberry Therapeutics is pleased to announce further progress on our Phase 2b European trial of BB2603 (BBTAF202). We previously announced the completion of recruitment, and we now provide an update that the final subject in this trial has passed through the Week 16 primary endpoint assessment time point.
This trial is assessing the efficacy and safety of different doses of BB2603, a new topical anti-fungal spray formulation, in subjects with fungal nail infection (onychomycosis). These subjects will continue through to the end of this 1-year trial, when the trial will readout and we will assess final efficacy and safety. We would like to express our gratitude to all participants for their continued involvement.
For more information about Blueberry Therapeutics please contact:
Dr Emma Leigh, Director of Communications